Overview Matrifen® for Therapy of Severe Chronic Pain® Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3). Details Lead Sponsor: NycomedTreatments: Fentanyl